Martina Pennisi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martina Pennisi has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Patrizia Chiusolo
Department of Laboratory and Hematological Sciences Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
27 shared publications - Annalisa Chiappella
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
26 shared publications - Beatrice Casadei
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
26 shared publications - Federico Stella
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA
26 shared publications - Ilaria Cutini
Struttura Organizzativa Dipartimentale Ematologia, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
26 shared publications - Jacopo Olivieri
Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
26 shared publications
Latest Publications
- 28 October 2026
- Published by Wiley in European Journal of Haematology
Older Age and Complex Karyotype Are the Main Predictors of Mortality Irrespective of Transplantation in Therapy‐Related Myeloid Neoplasms
Therapy‐related myeloid neoplasms (t‐MN) are late complications of cancer therapies. We retrospectively analyzed 86 adults diagnosed from 2007 to 2025 with t‐MN (acute myeloid leukemia [AML] n = 31, myelodysplastic neoplasms [MDS] n = 38, MDS/AML n = 17). We estimated overall survival (OS) and cumulative incidence of disease related mortality (DRM). Uni‐ and multivariable models identified predictors of mortality; interaction models defined the role of allogeneic hemopoietic stem cell transplantation (allo‐HSCT) in elderly patients and complex karyotype (CK) t‐MN. Median age at diagnosis was 65.5 years, previous cancer was solid in 29% or hematologic in 71%. Among 66/86 candidates to active therapy, 39/66 were candidates to allo‐HSCT and 24 received it. In our cohort, we had demonstrated a high prevalence of adverse baseline genomics (47% of CK) and poor OS (11.94 months), partially mitigated by allo‐HSCT (29.47 vs. 9.01 months, p = 0.028). In univariable and multivariable analysis, age ≥ 65 years and CK but not allo‐HSCT were DRM predictors. In interaction models, age ≥ 65 years remained deleterious regardless of transplant whereas allo‐HSCT could offset CK‐related risk, supporting transplantation even in high‐risk cytogenetics, when disease control and fitness criteria are met. Overall, t‐MN remained highly lethal, with DRM primarily driven by age and CK; allo‐HSCT attenuated cytogenetic risk.
- 28 October 2026
- Published by Wiley in European Journal of Haematology
Older Age and Complex Karyotype Are the Main Predictors of Mortality Irrespective of Transplantation in Therapy‐Related Myeloid Neoplasms
Therapy‐related myeloid neoplasms (t‐MN) are late complications of cancer therapies. We retrospectively analyzed 86 adults diagnosed from 2007 to 2025 with t‐MN (acute myeloid leukemia [AML] n = 31, myelodysplastic neoplasms [MDS] n = 38, MDS/AML n = 17). We estimated overall survival (OS) and cumulative incidence of disease related mortality (DRM). Uni‐ and multivariable models identified predictors of mortality; interaction models defined the role of allogeneic hemopoietic stem cell transplantation (allo‐HSCT) in elderly patients and complex karyotype (CK) t‐MN. Median age at diagnosis was 65.5 years, previous cancer was solid in 29% or hematologic in 71%. Among 66/86 candidates to active therapy, 39/66 were candidates to allo‐HSCT and 24 received it. In our cohort, we had demonstrated a high prevalence of adverse baseline genomics (47% of CK) and poor OS (11.94 months), partially mitigated by allo‐HSCT (29.47 vs. 9.01 months, p = 0.028). In univariable and multivariable analysis, age ≥ 65 years and CK but not allo‐HSCT were DRM predictors. In interaction models, age ≥ 65 years remained deleterious regardless of transplant whereas allo‐HSCT could offset CK‐related risk, supporting transplantation even in high‐risk cytogenetics, when disease control and fitness criteria are met. Overall, t‐MN remained highly lethal, with DRM primarily driven by age and CK; allo‐HSCT attenuated cytogenetic risk.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 5 – List of centers and patients enrolled
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 5 – List of centers and patients enrolled
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 3 – Summary of real-world data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 3 – Summary of real-world data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary figure 3 – Outcomes according to bridging therapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary figure 3 – Outcomes according to bridging therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 1 – Survival in entire population
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 1 – Survival in entire population